

**CORRIGENDUM**

**Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1  $\geq$  50% advanced non-small-cell lung cancer’**



[ESMO Open Volume 6, Issue 2, April 2021, 100078]

G. L. Banna<sup>1</sup>, A. Cortellini<sup>2,3\*</sup>, D. L. Cortinovis<sup>4</sup>, M. Tiseo<sup>5,6</sup>, J. G. J. V. Aerts<sup>7</sup>, F. Barbieri<sup>8</sup>, R. Giusti<sup>9</sup>, E. Bria<sup>10,11</sup>, F. Grossi<sup>12</sup>, P. Pizzutilo<sup>13</sup>, R. Berardi<sup>14</sup>, A. Morabito<sup>15</sup>, C. Genova<sup>16</sup>, F. Mazzoni<sup>17</sup>, V. Di Noia<sup>18</sup>, D. Signorelli<sup>19</sup>, A. Gelibter<sup>20</sup>, M. Macerelli<sup>21</sup>, F. Rastelli<sup>22</sup>, R. Chiari<sup>23</sup>, D. Rocco<sup>24</sup>, S. Gori<sup>25</sup>, M. De Tursi<sup>26</sup>, P. Di Marino<sup>27</sup>, G. Mansueto<sup>28</sup>, F. Zoratto<sup>29</sup>, M. Filetti<sup>9</sup>, M. Montrone<sup>13</sup>, F. Citarella<sup>30</sup>, R. Marco<sup>30</sup>, L. Cantini<sup>7,14</sup>, O. Nigro<sup>31</sup>, E. D’Argento<sup>10</sup>, S. Buti<sup>5</sup>, G. Minuti<sup>32</sup>, L. Landi<sup>32</sup>, G. Guaitoli<sup>8</sup>, G. Lo Russo<sup>19</sup>, A. De Toma<sup>19</sup>, C. Donisi<sup>33</sup>, A. Friedlaender<sup>34</sup>, A. De Giglio<sup>35</sup>, G. Metro<sup>36</sup>, G. Porzio<sup>37</sup>, C. Ficorella<sup>7,33</sup> & A. Addeo<sup>34</sup>

<sup>1</sup>Oncology Department, Portsmouth University Hospitals NHS Trust, Portsmouth; <sup>2</sup>Department of Surgery and Cancer, Imperial College London, London, UK; <sup>3</sup>Department of Biotechnology and Applied Clinical Sciences, University of L’Aquila, L’Aquila; <sup>4</sup>Medical Oncology, Ospedale San Gerardo, Monza; <sup>5</sup>Medical Oncology Unit, University Hospital of Parma, Parma; <sup>6</sup>Department of Medicine and Surgery, University of Parma, Parma, Italy; <sup>7</sup>Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the Netherlands; <sup>8</sup>Department of Oncology and Hematology, Modena University Hospital, Modena; <sup>9</sup>Medical Oncology, St. Andrea Hospital, Rome; <sup>10</sup>Comprehensive Cancer Center, Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Rome; <sup>11</sup>Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome; <sup>12</sup>Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan; <sup>13</sup>Thoracic Oncology Unit, Clinical Cancer Center IRCCS Istituto Tumori ‘Giovanni Paolo II’, Bari; <sup>14</sup>Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona; <sup>15</sup>Thoracic Medical Oncology, Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Napoli; <sup>16</sup>Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova; <sup>17</sup>Department of Oncology, Careggi University Hospital, Florence; <sup>18</sup>Medical Oncology, University Hospital of Foggia, Foggia; <sup>19</sup>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; <sup>20</sup>Medical Oncology (B), Policlinico Umberto I, ‘Sapienza’ University of Rome, Rome; <sup>21</sup>Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine; <sup>22</sup>Medical Oncology, Fermo Area Vasta 4, Fermo; <sup>23</sup>Medical Oncology, Ospedali Riuniti Padova Sud ‘Madre Teresa Di Calcutta’, Monselice; <sup>24</sup>Pneumo-Oncology Unit, Monaldi Hospital, Naples; <sup>25</sup>Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella VR; <sup>26</sup>Department of Medical, Oral & Biotechnological Sciences University G. D’Annunzio, Chieti-Pescara, Chieti; <sup>27</sup>Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti; <sup>28</sup>Medical Oncology, F. Spaziani Hospital, Frosinone; <sup>29</sup>Medical Oncology, Santa Maria Goretti Hospital, Latina; <sup>30</sup>Medical Oncology, Campus Bio-Medico University, Rome; <sup>31</sup>Medical Oncology, ASST-Sette Laghi, Varese; <sup>32</sup>Department of Oncology and Hematology, AUSL Romagna, Ravenna; <sup>33</sup>Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari; <sup>34</sup>Oncology Department, University Hospital of Geneva, Geneva, Switzerland; <sup>35</sup>Division of Medical Oncology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna; <sup>36</sup>Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia; <sup>37</sup>Medical Oncology, St. Salvatore Hospital, L’Aquila, Italy

The authors regret that the affiliations for Dr A. De Toma and Dr G. Lo Russo were incorrect when the article was published. Their correct affiliation is Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.esmoop.2021.100078>

\*Correspondence to: A. Cortellini.

E-mails: [a.cortellini@imperial.ac.uk](mailto:a.cortellini@imperial.ac.uk) or [alessiocortellini@gmail.com](mailto:alessiocortellini@gmail.com) (A. Cortellini).

2059-7029/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).